Jeffrey Cohen, MD | Cleveland Clinic

George Georges, MD | Fred Hutchinson Cancer Research Center

Paolo Muraro, MD, PhD | Imperial College London

Cleveland Clinic, Cleveland, OH

The objective of the BEAT-MS study is to compare the efficacy, safety, immunologic effects, and cost-effectiveness of myeloablative and immunoablative therapy followed by autologous hematopoietic stem cell transplant (AHSCT) versus the best available approved therapy. The study will focus on participants with relapsing multiple sclerosis (MS) and continued disease activity despite prior treatment with a currently approved disease modifying therapy.

BEAT-MS is a multi-center prospective rater-blinded randomized controlled clinical trial. 156 participants will be randomized 1:1 to receive either AHSCT or a currently approved disease modifying therapy.